Navigation Links
Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
Date:12/3/2008

utical partners for our ZFP Therapeutic programs."

Sangamo Accomplishments in 2008

During the briefing several of the company's achievements will be highlighted including:

Clinical

-- Presentation of the full data set from single dose Phase 1b study (SB-509-401) of SB-509 in subjects with diabetic neuropathy (DN) demonstrating that the drug is well-tolerated and statistically and clinically significant improvements in measures of nerve health at 180 days post treatment.

-- Initiation of repeat dosing Phase 2 clinical trials of SB-509 in stem cell mobilization (SB-509-703) and ALS (SB-509-801).

-- Completion of enrollment and expansion of Phase 2 clinical trial in subjects with moderate to severe DN (SB-509-701). Presentation of encouraging positive interim data from this trial.

-- Presentation of top line Phase 2 data from repeat dosing study of SB-509 in mild to moderate DN (SB-509-601) demonstrating that the drug is well-tolerated in a repeat-dosing setting; however, no significant differences were observed in improvement in measures of nerve health between placebo and treated subjects at primary evaluation point 180 days post treatment. Analysis of these data is ongoing.

Business

-- Dow AgroSciences announces early exercise of an option for a commercial license for ZFP technology in plant agriculture.

-- Official launch of Sigma-Aldrich CompoZr platform of zinc finger nuclease (ZFN) reagents for gene-editing.

-- Entry into Research and License Agreement with Genentech, Inc. for cell line engineering and License Agreement with Open Monoclonal Technologies (OMT) and Roche for transgenic animal generation.

Financial

-- Sangamo updated guidance on its expectations of 2008 year end cash to $60M in cash and cash equivalents, which the company believes is sufficient to fund
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
7. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 PharmaEngine, Inc. (TWO:4162) today announced ... MACK ) with its sublicensing partner, Baxter ... that Baxter has submitted a marketing authorization application ... MM-398 (irinotecan liposome injection), also known as "nal-IRI," ... who have been previously treated with gemcitabine-based therapy. ...
(Date:5/4/2015)... , May 4, 2015 Bayer HealthCare (Bayer) ... Pharmaceuticals, Inc. (NASDAQ: ISIS ) on ISIS-FXI Rx, ... the prevention of thrombosis. Under the agreement Bayer will ... of high unmet medical need. As part of the ... profile of ISIS-FXI Rx in an appropriate patient ...
(Date:5/4/2015)... 4, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... of the agreement, Isis is eligible to receive up ... $100 million up-front payment and a $55 million payment ... study in patients with compromised kidney function. Isis is ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5
... April 26, 2011 Cadence Pharmaceuticals, Inc. ... on in-licensing, developing and commercializing proprietary products principally for ... company,s President and CEO Theodore Schroeder will present a ... month of May: Deutsche Bank,s 36th ...
... Lilly and Company (NYSE: LLY ) and Medtronic, ... entered into a collaboration to research and develop a new ... new  medicine to the brain using an implantable drug delivery ... therapeutic approach for Parkinson,s disease that combines the strengths of ...
Cached Medicine Technology:Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease 2Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease 3
(Date:5/4/2015)... Every Friday afternoon at A Forever Recovery, a result-driven ... and staff gather in the common room to celebrate ... to gain encouragement and inspiration in their continuing effort ... those patients who have completed their recovery programs come ... share a bit about their journey with the audience. ...
(Date:5/4/2015)... Global Vision, the industry leader ... announced that it will showcase Proofware at the ... in Nashville Tennessee, May 04 and May 05. ... all-in-one we-based packaging inspection suite, giving enterprise-wide instant ... their brand copy and artwork. Proofware offers a ...
(Date:5/4/2015)... MO (PRWEB) May 04, 2015 Leonardo ... president and chief physician executive, and William C. Daniel, ... received and accepted personal invitations from the Secretary of ... Security Forum (NSF) at the Air War College, Maxwell ... to expose influential citizens to senior U.S. and international ...
(Date:5/4/2015)... 2015 Milton Hershey School® has named ... of the Year, recognizing his commitment to pediatric cancer ... sets for MHS students. , “Dr. Graves is a ... children are provided a top-notch education, a nurturing environment, ... said Pete Gurt ’85, president of MHS. “He is ...
(Date:5/4/2015)... McNeil & Company , a nationwide ... coverage for its Emergency Services Insurance Program ... and proactive risk management to the emergency services industry. ... providing our customers with unparalleled service and the best ... are excited to launch over 100 new enhancements that ...
Breaking Medicine News(10 mins):Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:Global Vision to Spotlight Proofware at INFO*FLEX 2015 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3
... edition Mustang at the New York, International Auto Show to raise money for ... ... G. Komen Race for the Cure - to $500 ... dedicated more than $95 million in, cash and in-kind contributions for breast cancer education ...
... Placing a "super-long coffee order,",a quirky trait ... a,difference for Children,s Hospital and Regional Medical Center., ... $1 to Children,s,Hospital for every Tully,s Coffee customer ... unique concoctions made up of seemingly,incongruous ingredients and ...
... BETHESDA, Md., March 18 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... Board of,Directors has unanimously approved a three-for-two split of ... per share, including its Class,B Common Stock. Stockholders of ... 2008 will receive one-half additional share of Common Stock ...
... March 18 W. Scott Harkonen,M.D., the former ... fraud and,felony Food, Drug and Cosmetic Act charges ... false and misleading information about the efficacy of,InterMune,s ... pulmonary fibrosis (IPF), the Justice Department announced,today., ...
... Statement Is Contrary to Widely Held American Values, ... and CEO, Religious,Coalition for Reproductive Choice, WASHINGTON, ... the national coalition of mainstream religious and,religiously affiliated ... reproductive healthcare and for women themselves in,the statement ...
... 18 Leading experts and,distinguished faculty in ... protocols and research to over 400 multi-disciplinary,clinicians ... Disorders,Professionals Symposium (iaedp(TM)) ( http://www.iaedp.com/ ) April ... in Orlando, Florida., "This year,s symposium ...
Cached Medicine News:Health News:Ford Launches 'Warriors in Pink' Mustang for '09, Doubles Contributions To Race For The Cure 2Health News:PEMCO Insurance and Tully's Coffee Team Up to Make Coffee Orders Count - For Children's Hospital 2Health News:PEMCO Insurance and Tully's Coffee Team Up to Make Coffee Orders Count - For Children's Hospital 3Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 2Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 3Health News:Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations 2Health News:Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations 3Health News:Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations 4Health News:National Religious Coalition Deeply Concerned by HHS Secretary's Disregard for Women's Reproductive Health 2Health News:Eating Disorders Take Center Stage at iaedp(TM) 2008 Symposium in Orlando, Florida 2
... Pick one of our pipettors up and ... and ejector positionsright where they should beeven if ... designed to help avoid repetitive stress injuries caused ... The Palm Of Your Hand Start dispensing ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
... The total ergonomic solution and best ... Soft, feather touch action and ultra lightweight ... Stress-free tip ejection with long, lever tip ... identification , Accepts universal tips or for ...
... Finnpipette BioControl multichannel has ... as the single channel ... fits allseven multichannel and ... cone modules. Both pipettes ...
Medicine Products: